Personalized antisense oligonucleotide targeting MAPK8IP3
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Personalized antisense oligonucleotide targeting MAPK8IP3, covering 2025-09-29 to 2025-09-29. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA) [Phase 1, Phase 2]